<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> comprise a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic diseases</z:e> of the lymphatic system </plain></SENT>
<SENT sid="1" pm="."><plain>In the WHO classification 70 different entities are subdivided </plain></SENT>
<SENT sid="2" pm="."><plain>Each type of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is defined as a disease with specific clinical characteristics, as well as morphological, immunophenotypic and genetic characteristics </plain></SENT>
<SENT sid="3" pm="."><plain>The indolent <z:hpo ids='HP_0002665'>lymphomas</z:hpo> include follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, small cell lymphocytic lymhoma/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Indolent <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are characterized by slow growth and a <z:hpo ids='HP_0011010'>chronic</z:hpo> course of the disease </plain></SENT>
<SENT sid="5" pm="."><plain>Antibody-based therapies, have significantly improved the prognosis, nevertheless there is no curative treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Watch and wait is still an reasonable option in asymptomatic patients </plain></SENT>
<SENT sid="7" pm="."><plain>The goal of therapy has been to maintain the best quality of life. and to avoid late toxicities </plain></SENT>
<SENT sid="8" pm="."><plain>The following review presents the current treatment options </plain></SENT>
</text></document>